January 29, 2007 — A large, multicenter, randomized, placebo-controlled study has shown that darbepoetin alfa, marketed as Aranesp, failed in cancer patients who have anemia not caused by chemotherapy ...
BARCELONA, Spain -- Sept. 26, 2007--Amgen today announced data from a Phase 2, randomized, multicenter, open-label study that suggest extended dosing of Aranesp(R) (darbepoetin alfa) paired with ...
This special issue is devoted to darbepoetin alfa, a novel erythropoiesis stimulating protein (NESP), and includes articles describing its preclinical development, as well as preliminary data from ...
ATLANTA – (Dec. 11, 2005) – Amgen (NASDAQ: AMGN), the world's largest biotechnology company, today announced updated interim data from a Phase 2 study evaluating the use of 500 mcg of Aranesp ...
Shares of Amgen are rallying $1.54, or 4.3 percent, to $37 in pre-open trading after the U.S. Food and Drug Administration approved the biotech firm's Aranesp for the treatment of chemotherapy-induced ...
As expected, the European Commission gave its marketing nod to Aranesp and Neulasta, the strong-selling U.S. oncology products from Amgen Inc. The company's stock (NASDAQ:AMGN) closed Wednesday at $45 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback